A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Summary

This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor cells to fluoresce (light up), so that surgeons may better distinguish tumor cells from healthy cells during surgery.

Timeline

Start

2024-04-17

Primary completion

2025-09-09

Completion

2025-09-26

Outcome

Outcome not reported

Stopped: “Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.”

Drugs

Indications